- Home
- IPHA vs JYNT Comparison
IPHA vs JYNT Comparison
Compare IPHA & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- JYNT
- Stock Information
- Founded
- IPHA 1999
- JYNT 2010
- Country
- IPHA France
- JYNT United States
- Employees
- IPHA N/A
- JYNT N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- JYNT Multi-Sector Companies
- Sector
- IPHA Health Care
- JYNT Miscellaneous
- Exchange
- IPHA Nasdaq
- JYNT Nasdaq
- Market Cap
- IPHA 160.1M
- JYNT 170.1M
- IPO Year
- IPHA 2019
- JYNT 2014
- Fundamental
- Price
- IPHA $2.18
- JYNT $10.56
- Analyst Decision
- IPHA Strong Buy
- JYNT Strong Buy
- Analyst Count
- IPHA 1
- JYNT 2
- Target Price
- IPHA $11.00
- JYNT $15.50
- AVG Volume (30 Days)
- IPHA 28.8K
- JYNT 60.1K
- Earning Date
- IPHA 03-27-2025
- JYNT 05-08-2025
- Dividend Yield
- IPHA N/A
- JYNT N/A
- EPS Growth
- IPHA N/A
- JYNT N/A
- EPS
- IPHA N/A
- JYNT N/A
- Revenue
- IPHA $20,831,349.00
- JYNT $52,789,479.00
- Revenue This Year
- IPHA $209.83
- JYNT $9.72
- Revenue Next Year
- IPHA $83.15
- JYNT $10.92
- P/E Ratio
- IPHA N/A
- JYNT N/A
- Revenue Growth
- IPHA N/A
- JYNT 71.05
- 52 Week Low
- IPHA $1.29
- JYNT $9.58
- 52 Week High
- IPHA $3.51
- JYNT $15.73
- Technical
- Relative Strength Index (RSI)
- IPHA 53.46
- JYNT 53.91
- Support Level
- IPHA $2.06
- JYNT $10.00
- Resistance Level
- IPHA $2.24
- JYNT $10.80
- Average True Range (ATR)
- IPHA 0.09
- JYNT 0.28
- MACD
- IPHA -0.01
- JYNT 0.09
- Stochastic Oscillator
- IPHA 53.33
- JYNT 64.21
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About JYNT The Joint Corp.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has two operating business segments; the Corporate Clinics segment is comprised of the operating activities of the company-owned or managed clinics, and The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The company generates maximum revenue from the Corporate clinic's segment.